North America Alzheimers Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America Alzheimers Drugs Market size is expected to reach US$ 12,331.0 Million by 2031 from US$ 3,932.8 Million in 2024. The market is estimated to record a CAGR of 17.9% from 2025 to 2031.

Executive Summary and North America Alzheimers Drugs Market Analysis:

The Alzheimers drugs market in North America is segmented into the US, Canada, and Mexico. The rising number of individuals aged over 65 increases the prevalence of Alzheimers, creating a larger patient base in need of treatment. Additionally, there is a strong emphasis on research and development, supported by government funding and private investment. The US, in particular, hosts leading pharmaceutical and biotechnology companies that develop innovative therapies, including disease-modifying treatments and monoclonal antibodies. The US FDA is willing to fast-track approval for promising Alzheimers drugs. Increasing public awareness, early diagnosis initiatives, and advancements in diagnostic tools are enabling earlier and more effective treatment. Additionally, healthcare infrastructure in North America is well-developed, with access to specialized care and reimbursement systems that encourage the use of new therapies. Moreover, the introduction of new treatments such as lecanemab and donanemab generates renewed interest and investment in the field, reinforcing North America's position in the Alzheimer's drugs market.

North America Alzheimers Drugs Market: Strategic Insights

North America Alzheimers Drugs Market Segmentation Analysis:

• By Drug Class, the North America Alzheimers Drugs Market is segmented into Cholinesterase Inhibitors, NMDA Receptor Antagonists, Combination Drugs, and Pipeline Drugs. The Cholinesterase Inhibitors segment dominated the market in 2024.
• By Cholinesterase Inhibitors Drug Class, the North America Alzheimers Drugs Market is segmented into Donepezil, Rivastigmine, and Galantamine. The Donepezil segment dominated the market in 2024.
• By End User, the North America Alzheimers Drugs Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment dominated the market in 2024.

North America Alzheimers Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The North America Alzheimers Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Alzheimers Drugs Market Outlook

As global demographics are shifting toward older age groups, the burden of neurodegenerative diseases particularly Alzheimers is increasing significantly. This trend is creating sustained demand for symptomatic and disease-modifying treatments, pushing pharmaceutical companies and healthcare systems to invest heavily in research, development, and distribution strategies. According to the World Health Organization (WHO), the global population aged 60 and older is expected to double by 2050, reaching nearly 2.1 billion. This demographic trend is reflected in Alzheimers prevalence: the Alzheimers Association reports that 6.7 million Americans aged 65 and older were living with Alzheimers in 2023. Without breakthroughs in prevention or treatment, that number is projected to rise to 13.8 million by 2060 contributing to the growing patient base, creating opportunities for drug manufacturers and healthcare providers. In 2023, Medicare spent an estimated US$360 billion on Alzheimers and other dementias which was more than triple the amount from a decade earlier. This rise in expenditure reflects the direct costs of medications and the broader care ecosystem, including hospitalizations, nursing homes, and caregiver support. As a result, the market has shifted focus from generic symptom relief drugs (such as donepezil or memantine) toward more innovative, high-cost treatments with disease-modifying potential. The recent US Food and Drug Administration approvals of Leqembi (lecanemab) and Kisunla (donanemab) reflect this commercial pivot. These monoclonal antibodies target beta-amyloid plaques, the core pathology in Alzheimers, and are priced at over US$26,000 annually per patient. Their rollout is commercially significant due to their high cost, and they are intended for early-stage patients, potentially expanding the market to millions who would not previously have been eligible for treatment.

Global expansion is driving revenue opportunities beyond the US. In 2024, Leqembi was approved in Saudi Arabia. Kisunla gained positive regulatory traction in Europe, opening doors for companies such as Eisai, Biogen, and Eli Lilly to tap into multi-regional commercial pipelines. With aging populations in Europe, East Asia, and the Middle East, Brazil following similar trends to North America, the multinational demand for Alzheimers therapeutics is rising steeply. Pharmaceutical companies strategically invest in companion diagnostics, such as amyloid PET scans and blood-based biomarker tests, to identify patients early, often before symptoms appear. This early identification increases the potential treatment window and boosts commercial value per patient by prolonging therapy duration. Thus, the aging population and rising Alzheimers prevalence are health crises and are defining commercial forces. With an expanding patient base, escalating healthcare expenditures, and a growing demand for disease-modifying therapies, the Alzheimers drugs market is set to become one of the most commercially dynamic segments in the global biopharma sector.

North America Alzheimers Drugs Market Country Insights

By country, the North America Alzheimers Drugs Market is segmented into the United States, Canada, and Mexico. The United States held the largest share in 2024.

According to a study titled "2025 Alzheimers disease facts and figures," published in April 2025, ~7.2 million people aged 65 and above are living with Alzheimers disease in the US, and this number is expected to reach 13.8 million by 2060. As per the same source, ~2.5 million people of age 85 or older are living with Alzheimers disease in 2025, accounting for 33% of all people with Alzheimers which is expected to reach 6.7 million 2060, accounting for about half (48%) of all people aged 65 and older with Alzheimers disease. Alzheimers is a leading cause of death among those 65 and older; one in three dies with dementia, surpassing breast and prostate cancer combined. This growing patient base, awareness, and early diagnosis creates demand for symptomatic and disease-modifying therapies. Additionally, increasing research investments are further expected to contribute the market growth. For instance, in 2024 the National Institutes of Health (NIH) estimates that about US$321 million will be needed in additional resources, with the overall funding needed for Alzheimers and related dementias research totaling US$3.87 billion, fostering innovation in diagnostics and therapeutics.

North America Alzheimers Drugs Market Company Profiles

Some of the key players operating in the market include Pfizer Inc, Merck & Co., Inc., Novartis AG, Johnson & Johnson, Merz Pharma GmbH & Co KGaA, AbbVie Inc, Eli Lilly and Co, Biogen Inc, Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceuticals Co., Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Alzheimers Drugs Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise